Trial Profile
A Phase 2 Study of LY573636-Sodium [tasisulam] Administered as Second-Line or Third-Line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 May 2018
Price :
$35
*
At a glance
- Drugs Tasisulam (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Apr 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 29 Sep 2009 Planned number of patients changed from 75 to 100 as reported by ClinicalTrials.gov.